Tyrosine kinase inhibitors (TKIs) that target abnormalities in several genes, such as ALK and EGFR, have shown better progression-free survival (PFS) as compared with standard chemotherapy in a number of NSCLC trials [4,5,6]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.